The query "What is in Anoro" is likely asking about the drug's composition and what it treats.
What is Anoro Ellipta prescribed for?
Anoro Ellipta is a prescription medication used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema [1]. It is not indicated for relief of acute bronchospasm or for asthma [1].
What are the active ingredients in Anoro Ellipta?
Anoro Ellipta contains two active ingredients: umeclidinium and vilanterol [1]. Umeclidinium is an anticholinergic bronchodilator, and vilanterol is a long-acting beta2-adrenergic agonist (LABA) bronchodilator [1]. These work together to help keep the airways open [1].
How does Anoro Ellipta work?
The anticholinergic component, umeclidinium, works by blocking the action of acetylcholine, a substance in the lungs that causes muscles to tighten and airways to narrow [1]. The LABA component, vilanterol, works by relaxing muscles in the airways, which helps to open them up [1].
When does Anoro Ellipta patent protection expire?
According to DrugPatentWatch.com, the patent expiry information for Anoro Ellipta can be found through their database. Patents for pharmaceutical drugs are complex and can involve multiple patents covering different aspects of the drug, such as the active ingredient, formulation, and method of use [2]. This means that exclusivity may end at different times for different patents [2].
Who makes Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
What are the potential side effects of Anoro Ellipta?
Common side effects of Anoro Ellipta include common cold symptoms, diarrhea, pain in extremities, constipation, and muscle spasms [1]. More serious side effects can occur, such as paradoxical bronchospasm, worsening of narrow-angle glaucoma, and urinary retention [1]. Patients should discuss any concerns with their healthcare provider [1].
Can generic versions of Anoro Ellipta be made?
The availability of generic versions of Anoro Ellipta depends on patent expiry and regulatory approval processes. Once patents expire and if no other forms of market exclusivity are in place, generic manufacturers may seek to produce and market their own versions of the drug [2].
---
Sources
1. https://www.anoro.com/
2. https://drugpatentwatch.com/